Jake with all due respect, running a biotech in todays world is not as simple as you make it sound. It is very easy to criticize management from the sidelines, but please remember that you are not privy to the info that PPHM's BOD and management are. They have very little control of the share price short term(it's not like they can just create "great" trial results), but have taken the strategy of executing their business plan and waiting for ph 2's to build value for the company before cutting any large licensing deals. Their position remains, that if BAVI continues to produce results in trials similar to what was achieved in pre clinical studies, all this dilution won't matter at all, because this could truly be a huge medical achievement. With successful ph 2's, you will start to see the bidding wars begin, and the strategy is to piecemeal out BAVI for every indication possible, and license for as many different continents/countries as possible....no worldwide license deals here. Meanwhile Cotara will probably be the early revenue earner to continue to expand BAVI's potential(and no we will not need FDA approval to license out BAVI is parts of Asia).
The question remains....is this the right strategy, or do you cut your deals now, just in case both BAVI and COTARA do not deliver as anticipated??? History will answer that one for us!!
Meanwhile, the bottom end of the pipeline is continuing to be filled up with more than just 2C3(trials coming here as well). There is a Helluva lot going on in many different parts of the world, and things should be starting to come together here real soon....meanwhile we sit in the $.70's and wait.
Remember that we are not trying to get this thing to $1.50 or $2(although that would be nice in the short term...ha ha), but we are going for the fence...many many multiples of this.....we will just have to wait and see,..... or sell and get out here if you don't believe...it is your choice after all.